Chitra R. Natalie

Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.

J. Silverberg, T. Bieber, J. Thyssen, 2023, The British journal of dermatology.

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis

M. Witte, M. Gooderham, S. Ferrucci, 2023, JAMA dermatology.

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

J. Thyssen, M. Gooderham, M. D. de Bruin‐Weller, 2023, American Journal of Clinical Dermatology.